Capienda Biotech

Capienda provides missing results for better small molecule designs: higher quality drugs enter clinical trials, saving up to $1 Billion +2 years per new drug.

  • Stage Prototype Ready
  • Industry Platforms
  • Location San Diego, CA, USA
  • Currency USD
  • Founded October 2017
  • Employees 2
  • Incorporation Type LLC
  • Website capienda.us

Company Summary

Saves time (1-2 yrs) + cost ($1 B) to develop new medicines by opening a bottleneck in drug discovery.
*First high-throughput kinetics system for small molecule drugs
*48x throughput of Biacore.

$329,272 NIH Grant 1R43TR005404
$256,000 NSF Grant NSF-2127159

Product: lab instrument system + assay chemicals. Recurring revenues after every instrument sale.

Scale: rapidly expand the chemistry menu for cancer targets.

Team

  • Mark Bernard PhD
    President

    20+ years in Pharmaceutical, Biotech industry.
    Drug discovery R&D at PFIZER & BAYER. Co-inventor of Vatelizumab therapeutic antibody --> $613M deal Glenmark/Sanofi.
    OMNIOME $800M EXIT to PacBio (2021); co-inventor (3 Patents) + $8.1M Series A.
    Jivi® Antihemophilic Factor (R&D team; Bayer).
    11 IVD chemistry products for clinical analyzers (Beckman Instruments).
    10 peer-reviewed publications, 7 Patents issued/pending.
    Two prior startups.

  • Donald Barnhart
    Director, Optical Engineering

    30+ years in coherent optics industry. 
    Optical scientist in areas of holography, flow cytometry, augmented reality and DUV lasers.
    Founder of the holographic velocimetry discipline.
    Publications in fields of holographic velocimetry, holographic recording in bacteriorhodopsin, and computer generated diffractive optics.
    Entrepreneurship: Founder (Optica Software company) for advanced optical design, modeling, analysis (25 years).

Advisors

  • Martin Gleeson, Ph.D.
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free